AR118005A1 - Administración del virus adenoasociado de polinucleótido de cln3 - Google Patents
Administración del virus adenoasociado de polinucleótido de cln3Info
- Publication number
- AR118005A1 AR118005A1 ARP200100305A ARP200100305A AR118005A1 AR 118005 A1 AR118005 A1 AR 118005A1 AR P200100305 A ARP200100305 A AR P200100305A AR P200100305 A ARP200100305 A AR P200100305A AR 118005 A1 AR118005 A1 AR 118005A1
- Authority
- AR
- Argentina
- Prior art keywords
- cln3
- associated virus
- administration
- polynucleotide
- adeno
- Prior art date
Links
- 239000002157 polynucleotide Substances 0.000 title abstract 3
- 102000040430 polynucleotide Human genes 0.000 title abstract 3
- 108091033319 polynucleotide Proteins 0.000 title abstract 3
- 241000702421 Dependoparvovirus Species 0.000 title abstract 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 abstract 3
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241000649044 Adeno-associated virus 9 Species 0.000 abstract 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 abstract 1
- 101150038645 CLN3 gene Proteins 0.000 abstract 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 abstract 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800911P | 2019-02-04 | 2019-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118005A1 true AR118005A1 (es) | 2021-09-08 |
Family
ID=69771089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100305A AR118005A1 (es) | 2019-02-04 | 2020-02-04 | Administración del virus adenoasociado de polinucleótido de cln3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12404523B2 (enExample) |
| EP (1) | EP3921430A1 (enExample) |
| JP (2) | JP7691367B2 (enExample) |
| KR (1) | KR20210124300A (enExample) |
| CN (1) | CN113646436A (enExample) |
| AR (1) | AR118005A1 (enExample) |
| AU (1) | AU2020217708A1 (enExample) |
| BR (1) | BR112021015285A2 (enExample) |
| CA (1) | CA3129077A1 (enExample) |
| CL (1) | CL2021002049A1 (enExample) |
| EA (1) | EA202192160A1 (enExample) |
| IL (1) | IL285328A (enExample) |
| MX (1) | MX2021009401A (enExample) |
| SG (1) | SG11202107986YA (enExample) |
| TW (1) | TW202045530A (enExample) |
| WO (1) | WO2020163300A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2879719B1 (en) | 2012-08-01 | 2018-07-04 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| WO2022170038A1 (en) * | 2021-02-05 | 2022-08-11 | Amicus Therapeutics, Inc. | Adeno-associated virus delivery of cln3 polynucleotide |
| JP2025524569A (ja) * | 2022-07-06 | 2025-07-30 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | Ｃｌｎ１ポリヌクレオチドのアデノ随伴ウイルス送達 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69433922T2 (de) | 1993-11-09 | 2005-07-28 | Medical College Of Ohio, Toledo | Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren |
| DK0733103T3 (da) | 1993-11-09 | 2004-07-12 | Univ Johns Hopkins | Fremstilling af höje titre af rekombinante AAV vektorer |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| CA2207927A1 (en) | 1994-12-06 | 1996-06-13 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant aav vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| WO1997008298A1 (en) | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
| CA2230758A1 (en) | 1995-09-08 | 1997-03-13 | Genzyme Corporation | Improved aav vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| CA2264483C (en) | 1996-09-06 | 2011-03-22 | James M. Wilson | Method for recombinant adeno-associated virus-directed gene therapy |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| EP1944362B1 (en) | 1997-09-05 | 2015-10-21 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant AAV vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| WO2013078316A1 (en) | 2011-11-23 | 2013-05-30 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| EP2879719B1 (en) * | 2012-08-01 | 2018-07-04 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| CA2967468A1 (en) * | 2014-12-16 | 2016-06-23 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| SG10202105090WA (en) * | 2016-11-17 | 2021-06-29 | Nationwide Childrens Hospital Inc | Intrathecal delivery of recombinant adeno-associated virus encoding methyl-cpg binding protein 2 |
-
2020
- 2020-02-04 AU AU2020217708A patent/AU2020217708A1/en active Pending
- 2020-02-04 TW TW109103419A patent/TW202045530A/zh unknown
- 2020-02-04 CA CA3129077A patent/CA3129077A1/en active Pending
- 2020-02-04 CN CN202080014802.1A patent/CN113646436A/zh active Pending
- 2020-02-04 AR ARP200100305A patent/AR118005A1/es unknown
- 2020-02-04 WO PCT/US2020/016542 patent/WO2020163300A1/en not_active Ceased
- 2020-02-04 EA EA202192160A patent/EA202192160A1/ru unknown
- 2020-02-04 BR BR112021015285-7A patent/BR112021015285A2/pt unknown
- 2020-02-04 EP EP20709850.0A patent/EP3921430A1/en active Pending
- 2020-02-04 KR KR1020217027483A patent/KR20210124300A/ko active Pending
- 2020-02-04 MX MX2021009401A patent/MX2021009401A/es unknown
- 2020-02-04 JP JP2021545401A patent/JP7691367B2/ja active Active
- 2020-02-04 US US17/427,010 patent/US12404523B2/en active Active
- 2020-02-04 SG SG11202107986YA patent/SG11202107986YA/en unknown
-
2021
- 2021-08-03 IL IL285328A patent/IL285328A/en unknown
- 2021-08-03 CL CL2021002049A patent/CL2021002049A1/es unknown
-
2025
- 2025-05-30 JP JP2025090921A patent/JP2025138648A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3921430A1 (en) | 2021-12-15 |
| EA202192160A1 (ru) | 2021-11-17 |
| US12404523B2 (en) | 2025-09-02 |
| CL2021002049A1 (es) | 2022-04-01 |
| US20220127641A1 (en) | 2022-04-28 |
| MX2021009401A (es) | 2021-11-12 |
| SG11202107986YA (en) | 2021-08-30 |
| KR20210124300A (ko) | 2021-10-14 |
| JP2025138648A (ja) | 2025-09-25 |
| WO2020163300A9 (en) | 2021-04-15 |
| WO2020163300A1 (en) | 2020-08-13 |
| IL285328A (en) | 2021-09-30 |
| JP2022519596A (ja) | 2022-03-24 |
| CA3129077A1 (en) | 2020-08-13 |
| JP7691367B2 (ja) | 2025-06-11 |
| CN113646436A (zh) | 2021-11-12 |
| AU2020217708A1 (en) | 2021-08-19 |
| BR112021015285A2 (pt) | 2021-10-05 |
| TW202045530A (zh) | 2020-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005517A (es) | Terapia genica para lipofuscinosis neuronal ceroidea. | |
| AR118005A1 (es) | Administración del virus adenoasociado de polinucleótido de cln3 | |
| NI202100085A (es) | Composición farmacéutica para inyección subcutánea que comprende una variante de hialuronidasa humana ph20 y un medicamento | |
| WO2018104540A4 (en) | Rnas for wound healing | |
| NZ601868A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| MX2009008270A (es) | Polipeptido novedoso que tiene actividad anti-tumoral. | |
| US10604741B2 (en) | Compositions and methods for enhancing virus replication | |
| BRPI0713731B8 (pt) | agente indutor de imunidade direcionado contra cânceres, medicamento para tratar e/ou prevenir tumores, e, agente para induzir células | |
| MY167485A (en) | Recombinant human interferon-like proteins | |
| AR123788A1 (es) | Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas | |
| JP2020513810A5 (enExample) | ||
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| AR071534A1 (es) | Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa | |
| CL2021002051A1 (es) | Administración del virus adenoasociado de polinucleótido de cln6. | |
| MX2023001137A (es) | Beta-glucocerebrosidasa mutada con estabilidad mejorada. | |
| BRPI0318594B8 (pt) | proteína recombinante que possui um efeito anticâncer, seu gene de codificação, seu uso, medicamento para tratar cânceres, vetor de expressão e microrganismo transgênico | |
| JP2013535965A5 (enExample) | ||
| AR118004A1 (es) | Administración del virus adenoasociado de polinucleótido de cln6 | |
| TWI496579B (zh) | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 | |
| WO2010086867A3 (en) | Peptides, pharmaceutical compositions comprising same and uses thereof | |
| ATE552271T1 (de) | Antitumorarzneimittel, medikament, zusammensetzung und anwendung davon | |
| BR112021020926A2 (pt) | Um novo tipo de composição de enzima | |
| BR112013002702A2 (pt) | vacina | |
| AR127169A1 (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 |